Sun Pharma has received FDA approval for its abbreviated new drug application (ANDA) to market a generic version of UCB’s Keppra injection, levetiracetam injection.
Subscribe to our email newsletter
Levetiracetam injection is indicated as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
It is also indicated as adjunctive therapy in the treatment of myoclonic seizures in patients with Juvenile myoclonic epilepsy.
Levetiracetam injection is an alternative for patients when oral administration is temporarily not feasible.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.